Trials / Recruiting
RecruitingNCT06185764
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-670 | Solution for intravenous administration. |
| DRUG | Placebo | Solution for intravenous administration. |
Timeline
- Start date
- 2024-02-20
- Primary completion
- 2026-12-22
- Completion
- 2026-12-22
- First posted
- 2023-12-29
- Last updated
- 2026-02-18
Locations
26 sites across 10 countries: United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06185764. Inclusion in this directory is not an endorsement.